TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABET , a combination formulation of FDA-approved ketamine and betaine anhydrous, which has shown in research to enhance the…

Source

Previous articleAwakn Life Sciences Strengthens Executive Leadership Team
Next articleCybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress